Kamada Ltd. to Post Q4 2016 Earnings of $0.01 Per Share, Jefferies Group Forecasts (KMDA)
Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at Jefferies Group issued their Q4 2016 EPS estimates for shares of Kamada in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy forecasts that the brokerage will post earnings of $0.01 per share for the quarter. Jefferies Group currently has a “Buy” rating on the stock.
A number of other equities research analysts have also recently issued reports on KMDA. Zacks Investment Research upgraded shares of Kamada from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Thursday, August 4th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Kamada in a research report on Saturday, September 3rd. Finally, TheStreet raised shares of Kamada from a “sell” rating to a “hold” rating in a research report on Monday, September 26th.
Kamada (NASDAQ:KMDA) opened at 5.40 on Friday. Kamada has a 12 month low of $3.26 and a 12 month high of $6.29. The stock’s 50 day moving average price is $5.49 and its 200 day moving average price is $4.42. The firm’s market capitalization is $196.66 million.
An institutional investor recently raised its position in Kamada stock. Vanguard Group Inc. boosted its stake in Kamada Ltd. (NASDAQ:KMDA) by 19.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 327,533 shares of the company’s stock after buying an additional 52,195 shares during the period. Vanguard Group Inc. owned 0.85% of Kamada worth $1,202,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.31% of the company’s stock.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Stock Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related stocks with our FREE daily email newsletter.